Oppenheimer Maintains Their Buy Rating on Jazz Pharmaceuticals (JAZZ)


In a report released today, Esther Rajavelu from Oppenheimer maintained a Buy rating on Jazz Pharmaceuticals (JAZZ), with a price target of $175. The company’s shares closed yesterday at $127.76.

Rajavelu commented:

“JAZZ reported 4Q results that were higher than our estimates on the top and bottom lines, primarily driven by solid product uptake across a majority of the portfolio. Management’s guidance suggests continued revenue growth in all franchises as well as earnings growth, despite higher operating expenses primarily driven by increasing SG&A investments in pre-launch and launch activities. We continue to view the EDS franchise as a stable platform, and look forward to JZP-258 data and Solriamfetol regulatory action this year. The hematology franchise in our view continues to be an area for investment and look for Vyxeos uptake in the EU and potential Erwinaze volatility in 2019 with continued supply constraints. We maintain our Outperform rating and $175 price target.”

According to TipRanks.com, Rajavelu is a 2-star analyst with an average return of -0.3% and a 50.0% success rate. Rajavelu covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Rocket Pharmaceuticals Inc, and Aerie Pharma.

Currently, the analyst consensus on Jazz Pharmaceuticals is a Moderate Buy with an average price target of $180.86, a 41.6% upside from current levels. In a report issued on February 12, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $185 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $184 and a one-year low of $113.52. Currently, Jazz Pharmaceuticals has an average volume of 710K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts